Literature DB >> 16021506

Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.

Jinru Shia1, Jing Qin, Robert A Erlandson, Roy King, Peter Illei, Jennifer Nobrega, Davis Yao, David S Klimstra.   

Abstract

Mesothelioma with a pronounced myxoid stroma has been identified as a morphological pattern that might portend a better prognosis. Reports on this type of cases are few. Its clinical and pathological features are not defined. In this study, we identified 19 such cases from a series of 234 pleural mesotheliomas and performed a comprehensive clinical and pathological analysis. The inclusion criteria were mesotheliomas with at least 50% of the tumor exhibiting a pronounced myxoid stroma that occupied more than 50% of the tumor volume (designated as myxoid mesothelioma). There were ten males and nine females, with a median age of 58 years. Forty seven percent of the patients had probable or definite asbestos exposure. Patients presented at various stages [International Mesothelioma Interest Group (IMIG) stage II, 4; stage III, 9; and stage IV, 6]. Most (16/19) patients were treated by extrapleural pneumonectomy with adjuvant radiation or chemotherapy or both. Overall, the median survival rate was 36 months (median follow-up time, 17 months), and the 2-year survival rate was 79%. Histologically, the tumor cell component was entirely epithelioid without significant cytologic atypia. The myxoid material stained positive for Alcian blue, and the staining diminished after treatment with hyaluronidase in 12 of 12 cases. The tumor cells showed a typical mesothelial immunophenotype. Ultrastructurally, all six tumors examined had typical mesothelial-type surface microvilli and a moderately electron-dense extracellular amorphous material that often formed a haze enmeshing the surface microvilli. Hyaluronic acid-type, fern-like crystals were noted in all cases. These findings show that myxoid mesotheliomas represent a group of epithelioid mesotheliomas that have retained the secretory activity of normal mesothelium. Patients may present at different stages, but survival appears to be superior to that of epithelioid mesotheliomas in general. Our study emphasizes the need for better attention to histologic subtypes, particularly in the context of prognostically or therapeutically oriented investigations of this lethal disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021506     DOI: 10.1007/s00428-005-0035-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Authors:  V W Rusch; E S Venkatraman
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

Review 2.  Predictive and prognostic factors in malignant pleural mesothelioma.

Authors:  Paul Baas
Journal:  Curr Opin Oncol       Date:  2003-03       Impact factor: 3.645

3.  A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Lung Cancer       Date:  1996-02       Impact factor: 5.705

Review 4.  Contemporary management of malignant pleural mesothelioma.

Authors:  E G Butchart
Journal:  Oncologist       Date:  1999

5.  Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.

Authors:  E G Butchart; T Ashcroft; W C Barnsley; M P Holden
Journal:  Thorax       Date:  1976-02       Impact factor: 9.139

6.  Mesothelioma versus adenocarcinoma: false-positive CEA and Leu-M1 staining due to hyaluronic acid.

Authors:  J A Robb
Journal:  Hum Pathol       Date:  1989-04       Impact factor: 3.466

7.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors:  V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

Review 8.  Deciduoid mesothelioma: a report of 5 cases and literature review.

Authors:  Jinru Shia; Robert A Erlandson; David S Klimstra
Journal:  Ultrastruct Pathol       Date:  2002 Nov-Dec       Impact factor: 1.094

9.  Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.

Authors:  S P Hammar; D E Bockus; F L Remington; K A Rohrbach
Journal:  Ultrastruct Pathol       Date:  1996 Jul-Aug       Impact factor: 1.094

10.  Extensive myxoid change in well-differentiated papillary mesothelioma of the pelvic peritoneum.

Authors:  Leslie K Diaz; Adaora Okonkwo; Enric P Solans; Carlos Bedrossian; M Sambasiva Rao
Journal:  Ann Diagn Pathol       Date:  2002-06       Impact factor: 2.090

View more
  6 in total

1.  Pathology of mesothelioma.

Authors:  Kouki Inai
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

2.  Localized malignant myxoid anaplastic mesothelioma of the pericardium.

Authors:  Guang Zhi Yang; Jing Li; Hua Ye Ding
Journal:  J Clin Med Res       Date:  2009-06-21

Review 3.  Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist?

Authors:  Stefan M Willems; Malgorzata Wiweger; J Frans Graadt van Roggen; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-08-25       Impact factor: 4.064

4.  Reproducibility of histological subtyping of malignant pleural mesothelioma.

Authors:  Luka Brčić; Marko Jakopović; Iva Brčić; Vlasta Klarić; Milan Milošević; Ana Sepac; Miroslav Samaržija; Sven Seiwerth
Journal:  Virchows Arch       Date:  2014-10-10       Impact factor: 4.064

5.  A patient with epithelioid pleural mesothelioma (Myxoid variant) who survived for a long period without treatment.

Authors:  Keiichi Mizuhashi; Kenzo Okamoto; Takumi Kishimoto
Journal:  Respir Med Case Rep       Date:  2021-03-08

6.  Unusual Histology in Mesothelioma: A Report of Two Cases with a Brief Review.

Authors:  Francesca Bono; Stefano Ceola; Carlo Beretta; Marta Jaconi
Journal:  Diagnostics (Basel)       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.